Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Acq. announced
Inv. presentation
Mirum Pharmaceuticals, Inc. (MIRM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - $37.5 million total revenue, including net product sales for LIVMARLI ® oral solution of $32.5 million, for second quarter 2023 - Acquiring CHENODAL ® and CHOLBAM ® , advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise - Four late-stage clinical trial data readouts expected later this year - Conference call to provide business updates today, August 3 at 1:30 p.m. PT/4:30 p.m. ET"
07/17/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET"
04/17/2023 8-K Quarterly results
04/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/08/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million - Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET"
01/09/2023 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/13/2022 8-K Quarterly results
11/29/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
09/02/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors"
05/23/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/05/2022 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI ® oral solution of $10.9 million. - Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET"
03/09/2022 8-K Quarterly results
01/11/2022 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones",
"Investor Presentation dated January 2022"
12/22/2021 8-K Completion of Acquisition or Disposition of Assets  Interactive Data
11/19/2021 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ASSET PURCHASE AGREEMENT BY AND BETWEEN JANSSEN BIOTECH, INC. AND MIRUM PHARMACEUTICALS, INC. November 16, 2021"
11/15/2021 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - U.S. commercial launch underway following U.S. FDA approval of LIVMARLITM oral solution - Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p - The Lancet published data from the pivotal LIVMARLI ICONIC study demonstrating significant and durable responses in pruritus and other clinically meaningful improvements in patients with ALGS - Conference call to provide business updates and discuss data presented at AASLD today, November 15 at 1:30 p.m. PT/4:30 p.m. ET"
09/29/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Amendment No. 1 to Revenue Interest Purchase Agreement",
"U.S. FDA Approves LIVMARLI as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older"
08/19/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update - NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is September 29, 2021 - Commercial preparations complete in anticipation of U.S. launch of maralixibat in ALGS - Conference call to provide business update today, August 5 at 1:30 p.m. PT/4:30 p.m. ET"
06/09/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
12/15/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 14, 2020 Mirum Pharmaceuticals, Inc. Delaware 001-38981 83-1281555 950 Tower Lane, Suite 1050 Foster City, California 94404 Registrant's telephone number, including area code: 667-4085 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre...",
"Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group L.L.C.",
"Opinion of Cooley LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy